Are Wall Street Analysts Predicting Becton, Dickinson and Company Stock Will Climb or Sink?
Becton, Dickinson and Company (BDX) medical technology shares have outperformed the S&P 500 and the iShares U.S. Medical Devices ETF over the past year and YTD. After Q3 results on Aug. 6, BDX reported adjusted EPS of $3.23 vs $3.14 expected, revenue of $5.0B vs $4.9B, and full-year adjusted EPS guidance of $12.62 to $12.72. Analysts rate it a “Moderate Buy” with a mean target of $187.33 and a Citigroup target of $208.
How this was made
%252FBD%252520Canada's%252520head%252520office%252520building%252520in%252520Mississauga%25252C%252520On%25252C%252520Canada_%252520%252520By%252520JHVEPhoto.jpeg&w=3840&q=75)
The 30-second read
Why it matters
The newest actionable elements are the Q3 beat with specific adjusted EPS and revenue figures, the full-year adjusted EPS guidance range, and the cited analyst consensus and price targets implying upside.
Market read
Company-specific earnings beat and guidance plus bullish sell-side positioning can influence short-term trading and options pricing, though the expected EPS decline adds risk to sustained momentum.
What to watch
The text highlights operational challenges and international headwinds but does not quantify them; traders may need to watch whether GLP-1 auto-injector growth offsets margin pressure.
Background
BDX is described as a medical technology and diagnostics company that has lagged peers due to sluggish revenue growth, margin stagnation, and international headwinds, but has recently regained investor confidence.
Ticker impact
BDX shares closed up 3.8% on Aug. 6 after Q3 results, with adjusted EPS and revenue beating consensus and full-year EPS guided to 12.62-12.72.
Bias toward continued upside follow-through or support on dips, unless subsequent quarters show the guided EPS decline versus the prior year.
It cites concrete Q3 beats (EPS and revenue), a specific full-year adjusted EPS range, and a stated analyst consensus of Moderate Buy with a Citigroup Buy and upside implied by targets.
Market effects
Reinforces positive read-through for medical devices via drug-delivery device strength (GLP-1 auto-injectors) and margin stabilization narrative.
No specific regional catalyst beyond general mention of international headwinds (China) and recovery.
Limited; the piece is primarily company-specific rather than a global medtech macro driver.
Counterpoint
Despite the Q3 beat, the article notes analysts expect full-year EPS to decline about 12% for the current fiscal year, which can cap upside if investors focus on deceleration.
Key entities
- companyBecton, Dickinson and Company
Reported Q3 results with adjusted EPS and revenue above expectations and provided full-year adjusted EPS guidance; also discussed in analyst rating and price-target context.
- financial_institutionCitigroup Inc.
Cited as reiterating a Buy rating on BDX with a stated price target.
